# Tianweiyuan and Biomedicine (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianweiyuan-and-biomedicine-shanghai-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.itabmed.com
- Total disclosed funding: $20M
- Latest round: Series A (Dec 1, 2021)
- Investors on record: 3

## About

Based in Shanghai, China, and founded in 2020, Tianweiyuan and Biomedicine (Shanghai) Co., Ltd., d.b.a. ITabMed Ltd., operates as a biotechnology company that focuses on tumor immunotherapy. The company was formed by a spin-off from Generon BioMed Ltd, and as of November 2021, the firm is being led by its founder and CEO, Xiaoqiang Yan. In December 2021, the company raised USD 20 million in series A funding co-led by new investors 3E Bioventures Capital and Regent Capital, with participation from another new investor BINHAI Capital.

The company provides tumor immunotherapy drugs for hematopoietic cancers and non-hematopoietic cancers such as acute lymphoblastic leukemia (ALL), liver and bile duct cancer, lung, pancreas, stomach, and colon cancer, etc. The firm has developed an immunotherapy antibody technology platform called iTAb™, which applies the T cell engager (TCE) mechanism to kill and eliminate tumor cells in cancer patients. The iTAb product pipeline includes CD3 T cell engagers, A-319, and A-337, which are currently in the phase I clinical development stage.

The company plans to deploy the funds for further development of products derived from the iTAb™ platform.

## Funding rounds

- Series A, Dec 1, 2021, $20M — 3E Bioventures Capital, Regent Capital, BINHAI Capital

## Investors

- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- Regent Capital — Series A
- BINHAI Capital (https://capitalatlas.ai/funds/binhai-capital) — Series A